Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer.
adaptive immunity
gastrointestinal neoplasms
immunity
innate
translational medical research
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
accepted:
11
10
2020
entrez:
11
11
2020
pubmed:
12
11
2020
medline:
18
9
2021
Statut:
ppublish
Résumé
Immunogenic cell death (ICD) is a tumor cell death involving both innate and adaptive immune responses. Given published findings that oxaliplatin, but not irinotecan, drives ICD, we investigated whether single nucleotide polymorphisms (SNPs) in the ICD pathway are associated with the efficacy of oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC). Two randomized clinical trials data were analyzed: discovery cohort, FOLFOX/bevacizumab arm (MAVERICC); validation cohort, FOLFOXIRI/bevacizumab arm (TRIBE); and two control cohorts, FOLFIRI/bevacizumab arms (both trials). Genomic DNA extracted from blood samples was genotyped. Ten SNPs in the ICD pathway were tested for associations with clinical outcomes. In total, 648 patients were included. In the discovery cohort, three SNPs were significantly associated with clinical outcomes in univariate analysis: The predictive utility of ICD-related SNPs for the efficacy of oxaliplatin-based chemotherapy was demonstrated, warranting further validation studies to be translated into personalized treatment strategies using conventional cytotoxic agents in mCRC.
Sections du résumé
BACKGROUND
Immunogenic cell death (ICD) is a tumor cell death involving both innate and adaptive immune responses. Given published findings that oxaliplatin, but not irinotecan, drives ICD, we investigated whether single nucleotide polymorphisms (SNPs) in the ICD pathway are associated with the efficacy of oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC).
METHODS
Two randomized clinical trials data were analyzed: discovery cohort, FOLFOX/bevacizumab arm (MAVERICC); validation cohort, FOLFOXIRI/bevacizumab arm (TRIBE); and two control cohorts, FOLFIRI/bevacizumab arms (both trials). Genomic DNA extracted from blood samples was genotyped. Ten SNPs in the ICD pathway were tested for associations with clinical outcomes.
RESULTS
In total, 648 patients were included. In the discovery cohort, three SNPs were significantly associated with clinical outcomes in univariate analysis:
CONCLUSIONS
The predictive utility of ICD-related SNPs for the efficacy of oxaliplatin-based chemotherapy was demonstrated, warranting further validation studies to be translated into personalized treatment strategies using conventional cytotoxic agents in mCRC.
Identifiants
pubmed: 33172883
pii: jitc-2020-001714
doi: 10.1136/jitc-2020-001714
pmc: PMC7656952
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Oxaliplatin
04ZR38536J
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):126-135
pubmed: 27697780
J Natl Cancer Inst. 2019 Aug 1;111(8):828-836
pubmed: 30649440
J Clin Oncol. 2015 Nov 20;33(33):3968-71
pubmed: 26392104
Sci Rep. 2017 Aug 16;7(1):8435
pubmed: 28814781
JAMA Oncol. 2017 Feb 1;3(2):194-201
pubmed: 27722750
EMBO J. 2012 Mar 7;31(5):1062-79
pubmed: 22252128
J Natl Cancer Inst. 2013 Nov 20;105(22):1677-83
pubmed: 24136891
Oncogene. 2010 Jan 28;29(4):482-91
pubmed: 19881547
Clin Cancer Res. 2019 May 15;25(10):2988-2995
pubmed: 30224341
Nat Rev Drug Discov. 2012 Feb 03;11(3):215-33
pubmed: 22301798
Mol Carcinog. 2020 Jul;59(7):783-793
pubmed: 32215970
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
J Clin Oncol. 2017 May 1;35(13):1453-1486
pubmed: 28165299
Methods Enzymol. 2019;629:71-79
pubmed: 31727257
Nat Med. 2016 Jun;22(6):624-31
pubmed: 27135741
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
J Natl Cancer Inst. 2015 Feb 24;107(3):
pubmed: 25713148
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52
pubmed: 19815849
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Oncoimmunology. 2017 Oct 4;6(12):e1386829
pubmed: 29209573
Lancet Oncol. 2019 May;20(5):e274-e283
pubmed: 31044725
Ann Oncol. 2017 Aug 1;28(8):1713-1729
pubmed: 28407110
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750